Abstract | Eosinophils have been traditionally perceived as terminally differentiated cytotoxic effector cells. Recent studies have profoundly altered this simplistic view of eosinophils and their function. New insights into the molecular pathways that control the development, trafficking and degranulation of eosinophils have improved our understanding of the immunomodulatory functions of these cells and their roles in promoting homeostasis. Likewise, recent developments have generated a more sophisticated view of how eosinophils contribute to the pathogenesis of different diseases, including asthma and primary hypereosinophilic syndromes, and have also provided us with a more complete appreciation of the activities of these cells during parasitic infection. REVIEWS NATURE REVIEWS | IMMUNOLOGY VOLUME 13 | JANUARY 2013 | 9
Eosinophils were first described in 1879 by Paul Ehrlich, who noted their unusual capacity to be stained by acido philic dyes. Interestingly, our appreciation of this unique property of eosinophils is clear and steadfast, but a com prehensive understanding of the function of these cells in health and disease remains elusive. Some basic char acteristics of eosinophils are established and accepted. It is clear that eosinophils are granulocytes that develop in the bone marrow from pluripotent progenitors. They are released into the peripheral blood in a phenotypi cally mature state, and they are capable of being activated and recruited into tissues in response to appropriate stimuli, most notably the cytokine interleukin5 (IL5) and the eotaxin chemokines. Eosinophils spend only a brief time in the peripheral blood (they have a half life of ~18 hrs) 1 before they migrate to the thymus or gastrointestinal tract, where they reside under homeo static conditions 2 . In response to inflammatory stimuli, eosinophils develop from committed bone marrow progenitors, after which they exit the bone marrow, migrate into the blood and subsequently accumulate in peripheral tissues, where their survival is prolonged (reviewed in REFS 3-5).
However, much remains unclear. For example, the longheld belief that eosinophils promote immunity to helminths has been called into question by results from animal studies, some of which suggest that eosinophils may be serving to promote the needs and longevity of specific parasites 6, 7 . Likewise, eosinophils are clearly recruited to and activated in lung tissue as part of the pathophysiology of asthma, and most current evidence suggests that eosinophils contribute to airway dysfunction and tissue remodelling in this disorder 8, 9 . Evolution tells us that the ability to induce pathology cannot be a 'raison d'être' for any existing cell lineage, and recent findings on the antimicrobial and antiviral activities of eosinophils suggest that the pathology that arises from dysregulated eosinophilia in the airways may be collateral damage related to host defence. Similarly, although there are now two unique eosinophildeficient mouse strains 10, 11 , there are no known unique eosinophildeficiency states in humans to help us to decipher the importance of these cells in vivo.
This Review examines the most recent advances in our understanding of the contributions of eosinophils to the maintenance of health, and how dysregulated eosinophil function promotes various disease states. These advances were made possible by reagents, systems and methods that target eosinophil function and by the first clinical trials using humanized monoclonal anti bodies specific for IL5 (TABLE 1) . These tools have been invaluable for shaping our current views on eosinophil function and for generating new hypotheses for future examination.
The unique biology of the eosinophil Relatively few mature eosinophils are found in the peripheral blood of healthy humans (less than 400 per mm 3 ), but these cells can be readily distinguished from the more prevalent neutrophils by virtue of their bilobed nuclei and large specific granules (FIG. 1) . Human eosinophil granules contain four major proteins: eosino phil peroxidase, major basic protein (MBP) and the (FIG. 1) .
Eosinophils express surface receptors for ligands that support growth, adhesion, chemotaxis, degranu lation and celltocell interactions (FIG. 2) . Many of the signalling pathways involved in these responses have been detailed in recent reviews 3,4,13 . Among the main receptors that define the unique biology of the eosino phil are interleukin5 receptor subunitα (IL5Rα) and CCchemokine receptor 3 (CCR3), as well as sialic acid binding immunoglobulinlike lectin 8 (SIGLEC8) in humans and SIGLECF (also known as SIGLEC5) in mice. Patternrecognition receptors (PRRs) are also likely to be important for eosinophil function, a subject that remains to be fully explored
Factors that promote eosinophilia IL5 has a central and profound role in all aspects of eosinophil development, activation and survival
. Likewise, CCchemokine ligand 11 (CCL11; also known as eotaxin), which is a ligand for CCR3, pro motes eosinophilia both cooperatively with IL5 and via IL5independent mechanisms 14, 15 . Recently, several new factors that promote eosinophilic inflammation in vivo have been identified.
The epithelial cellderived cytokines thymic stromal lymphopoietin (TSLP), IL25 (also known as IL17E) and IL33 promote eosinophilia by inducing IL5 production. TSLP is an IL2 family cytokine that sig nals through a heterodimeric receptor that comprises the IL7 receptor αchain and a specific TSLP recep tor βchain. The TSLP receptor is expressed widely, by myeloid dendritic cells (DCs), CD4 + and CD8 + T cells, B cells, mast cells and airway epithelial cells. The TSLP receptor is also expressed by human eosinophils and modulates their survival and activation 16 . IL25 is produced primarily by activated T helper 2 (T H 2) cells and mast cells and induces the production of T H 2type cytokines (including IL5) from T H 2 cells, as well as from the newly described populations of mouse innate lymphoid cells, which include nuocytes and natural helper cells [17] [18] [19] . In this manner, IL25 can amplify the development, recruitment and survival of eosinophils in allergic states. Abundant expression of both IL25 and the IL25 receptor was also detected in a recent study of bronchial and skin biopsies from allergic human sub jects 20 , and eosinophils themselves were identified as the primary source of IL25 in patients with severe systemic vasculitis (Churg-Strauss syndrome) 21 . IL33 -which is a member of the IL1 cytokine family -is expressed by epithelial cells, endothelial cells, fibroblasts and adipocytes, and is an endogenous danger signal known as an alarmin. IL33 specifically modulates T H 2type proinflammatory signals follow ing its release from necrotic cells. The IL33 receptor ST2 (also known as IL1RL1) is found primarily on T H 2 cells, but IL33dependent responses from mouse nuocytes, natural helper cells and innate type 2 helper cells, and in human eosinophils themselves, have been described [22] [23] [24] . Furthermore, an IL33 and IL25responsive innate lymphoid cell population has recently been defined in humans 25 . Although the biology of this cytokine has not been fully elucidated, IL33 typically contributes to the synthesis and release of IL5 from one or more of the aforementioned target cells, and thereby promotes systemic eosinophilia.
IL23 is a member of the IL12 family of cytokines that promotes the function of T H 17 cells and also regulates aller gic airway inflammation. Silencing the expression of IL23 in mice that were sensitized and challenged with oval bumin resulted in decreased recruitment of eosinophils to the lung tissue in association with diminished levels of IL17 and IL4 (REF. 26 ). Accordingly, the overexpression of IL23 was shown to augment antigenstimulated eosino phil recruitment 27 . However, another study found that IL23 suppressed eosinophilia in a mouse model of fungal infection, a response that was IL17 independent 28 . Adhesion receptors
Highmobility group protein B1 (HMGB1) is another example of an alarmin that promotes eosinophilia. However, in contrast to IL33, there is no evidence that eosinophil activation in response to HMGB1 involves IL5. First identified as a nuclear protein and transcrip tion factor, HMGB1 is expressed ubiquitously and mediates inflammatory responses via its receptors. The HMGB1 receptors that have been identified so far are receptor for advanced glycation endproducts (RAGE), Tolllike receptor 2 (TLR2) and TLR4. Importantly, eosinophil mobilization and activation were observed in response to HMGB1 in tumour cell lysates 29 . Further work is needed in this area, as a better appreciation of the way in which eosinophils are activated in response to HMGB1 and other, related damageassociated molecular patterns (DAMPs) may explain the eosinophil recruit ment that is observed in the setting of tissue destruction associated with myalgias and myopathies. In one such interaction, eosinophils release the contents of their specific granules in response to external stimuli. Some of these granule contents are released via membrane-bound vesicles known as eosinophil sombrero vesicles. Eosinophils also synthesize lipid mediators for release in cytoplasmic lipid bodies and store Charcot-Leyden crystal protein (CLC) in primary granules. Although not highly biosynthetic, mature eosinophils have minimal numbers of mitochondria and a limited endoplasmic reticulum (ER) and Golgi, as well as a nucleus. Eosinophils express a wide variety of receptors that modulate adhesion, growth, survival, activation, migration and pattern recognition. Mouse eosinophils do not express CLC or Fcε receptor 1 (FcεR1) and have divergent homologues of sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC-8) and the granule ribonucleases eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP) 12 . APRIL, a proliferation-inducing ligand; CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; CXCL, CXC-chemokine ligand; CXCR, CXC-chemokine receptor; EGF, epidermal growth factor; EPX, eosinophil peroxidase; FPR1, formyl peptide receptor 1; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; MBP, major basic protein; NGF, nerve growth factor; NOD, nucleotide-binding oligomerization domain protein; PAR, proteinase-activated receptor; PDGF, platelet-derived growth factor; PIRB, paired immunoglobulin-like receptor B; PPARγ, peroxisome proliferator-activated receptor-γ; PRR, pattern-recognition receptor; PSGL1, P-selectin glycoprotein ligand 1; RAGE, receptor for advanced glycation end-products; RIG-I, retinoic acid-inducible gene I; TGF, transforming growth factor; TLR, Toll-like receptor; TNF, tumour necrosis factor; SCF, stem cell factor; VEGF, vascular endothelial growth factor.
Cytolytic degranulation
A mechanism through which eosinophils lyse, thereby releasing either free granule proteins or fully intact granules. This renders the cells non-viable. Intact granules released in this manner can respond to physiological secretagogues.
Piecemeal degranulation
A mechanism through which eosinophils (as well as basophils and mast cells) release specific mediators from cytoplasmic granules by transporting them to the cell surface in membrane-bound cytoplasmic vesicles. The eosinophils remain viable and fully responsive to subsequent stimuli.
Secretagogues
Substances that induce the secretion of another substance from a cell or storage granule.
Eosinophil degranulation
Degranulation -that is, the release of granule con tents into the extracellular space -is a prominent eosinophil function. Previously, the release of secre tory mediators was assumed to take place primar ily through cytolytic degranulation, a mechanism through which a pathogenic assault (real or perceived) results in the complete emptying of the eosinophil's arsenal of preformed cationic proteins. Interestingly, a careful analysis of electron micrographs of eosino phils degranulating in tissues suggested a more con trolled process, which was given the name 'piecemeal degranulation' 30 to reflect the fact that the eosinophil was able to release bits or pieces of its granule con tents in response to a given stimulus, while remain ing otherwise intact and apparently viable. Piecemeal degranulation is now accepted as the most commonly observed physiological form of eosinophil degranula tion. Eosinophils undergoing piecemeal degranulation in response to cytokines, such as interferonγ (IFNγ) and CCL11, develop cytoplasmic secretory vesicles, known as eosinophil sombrero vesicles 31 (FIG. 2) , and remain viable and fully responsive to subsequent stimuli.
A recent study has provided substantial insights into the molecular mechanism of piecemeal degranulation 32 . Specifically, IL4 released from CCL11activated eosino phils first forms a complex with IL4 receptor subunitα (IL4Rα) within the granule membrane, and IL4Rα thereby chaperones IL4 to the membrane vesicles before its release from the cell. Although receptormediated trafficking pathways have not yet been defined for other eosinophil mediators 33 , this study provides an insight into the potential for exquisite molecular modulation of piecemeal degranulation 32 . Eosinophils also release intact granules, which are capable of storing and releasing mediators in response to physiological secretagogues in the cellfree state 34 . Cell free granules have been identified in tissues in associa tion with eosinophilassociated disorders 35 , although their functional significance and their ability to respond to activating stimuli in situ await further evaluation.
Box 1 | Receptors important for eosinophil function
Interleukin-5 receptor subunit-α The T helper 2 (T H 2) cell-associated cytokine interleukin-5 (IL-5) has a unique and profound impact on nearly all aspects of eosinophil biology. Originally known as T cell replacing factor and murine B cell growth factor II, and later as eosinophil differentiation factor, IL-5 is produced by activated T H 2 cells and, in smaller amounts, by mast cells, natural killer (NK) cells, natural killer T (NKT) cells and eosinophils themselves. In addition, several new sources of IL-5 have been identified in mouse models. These sources include KIT + innate natural helper cells 17 , nuocytes 17 and IL-25-or IL-33-responsive innate IL-5-producing cells 18 . IL-5 functions synergistically with the T H 2-type cytokines IL-4 and IL-13, and with the eosinophil chemoattractants CC-chemokine ligand 11 (CCL11), CCL24 and CCL26 (also known as eotaxin, eotaxin 2 and eotaxin 3, repectively) to promote eosinophil activation and recruitment into tissues in acute inflammatory responses 5, 123 . As such, IL-5 receptor subunit-α (IL-5Rα) is the most prominent cytokine receptor associated with eosinophils 112, 124 . In humans and mice, IL-5Rα is expressed by eosinophils and basophils. Mouse B1 cells also express IL-5Rα, and it functions to promote the proliferation and survival of these cells. The IL-5 receptor is heterodimeric; the α-subunit couples with a signalling β-subunit that is shared with the receptors for IL-3 and granulocyte-macrophage colonystimulating factor (GM-CSF). IL-5 receptor signalling promotes the development of eosinophils from committed progenitors, induces eosinophil activation and sustains eosinophil survival in peripheral blood and tissues.
Humanized IL-5-specific monoclonal antibodies (namely, mepolizumab and reslizumab) and a humanized IL-5Rα-specific monoclonal antibody (namely, benralizumab) are under exploration for the therapeutic management of dysregulated eosinophilia [92] [93] [94] [95] [96] 125 .
Chemokine receptors CC-chemokine receptor 3 (CCR3) mediates eosinophil chemotaxis in response to the eotaxins, CCL11, CCL24 and CCL26 (REF. 126 ). CCR3 can also be activated by CCL5 (also known as RANTES), CCL7 (also known as MCP3), CCL8 (also known as MCP2) and CCL12 (also known as MCP5). Eosinophils also express CCR1 -which is the primary receptor for CCL3 (also known as MIP1α) and CCL5 -and the platelet-activating factor receptor.
SIGLEC-8 and SIGLEC-F
Sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC-8) is a cell-surface immunoglobulin-like lectin that is expressed predominantly by human eosinophils. Mouse eosinophils express a functional paralogue, SIGLEC-F
127
. SIGLEC-8 and SIGLEC-F are members of a larger family of structurally related carbohydrate-binding proteins. Although the function of these proteins from the perspective of the eosinophil remains uncertain, antibodies specific for SIGLEC-8 or its recently identified carbohydrate ligand (6-sulpho sialyl Lewis X) promote selective eosinophil apoptosis. In particular, SIGLEC-8-specific antibodies exert this effect in physiologically relevant in vivo models 128 . Thus, these SIGLEC proteins represent important targets for potential therapeutic ablation 129 .
Pattern-recognition receptors
Several families of pattern-recognition receptors (PRRs) are expressed by eosinophils 130 . Toll-like receptors (TLRs) are expressed by both human and mouse eosinophils, although at lower levels than by neutrophils and macrophages. TLR7 -which is localized in endosomes and detects single-stranded RNA -is by far the most prominent TLR expressed by eosinophils. It is not yet clear what exact role TLR7 has in promoting eosinophil function in vivo. However, priming eosinophils with IL-5 promotes responsiveness to the TLR7 ligand R837 and enhances the release of the pro-inflammatory cytokine IL-8 via unknown mechanisms. Activation of TLR7 regulates the adhesion, migration and chemotaxis responses of eosinophils and prolongs eosinophil survival 131 .
Promyelocyte A cell in the bone marrow that has differentiated from a haematopoietic stem cell and that will ultimately generate mature granulocytes, including neutrophils, basophils and eosinophils. A promyelocyte can be identified in bone marrow smears as a relatively large cell with a full, non-condensed nucleus and lineage-specific cytoplasmic granules. 
Alternatively activated macrophages
One of the major differences between these cells and classically activated macrophages is that these macrophages are not primed with IFNγ. Instead, alternatively activated macrophages are stimulated by T H 2-type cytokines (such as IL-4 or IL-13) and present soluble antigens to T cells. Alternatively activated macrophages release CCL17, CCL18, CCL22, IL-10, TGFβ, YM1, YM2 and RELMα, and they characteristically function to promote the resolution of inflammation.
Interactions of eosinophils with other leukocytes
During their transit from the bloodstream to the tissue, eosinophils use selectins and integrins to interact with endothelial cells, and they interact with epithelial cells at mucosal surfaces in a similar manner; these subjects have been reviewed extensively 36 . Eosinophils also interact with and modulate the functions of other leukocytes (FIG. 3) .
Interaction with lymphocytes. Eosinophils clearly respond to signals (such as IL5) that are provided by T cells. Two recent studies indicate that T cells also respond to signals provided by eosinophils 37, 38 . Although not 'professional' antigenpresenting cells, eosinophils can express cellsurface components that are required for antigen presentation (such as MHC class II molecules and the costimulatory molecules CD80 and CD86). Indeed, eosinophils can process antigens and stimulate T cells in an antigenspecific manner, resulting in T cell prolifera tion and cytokine release 39 . Furthermore, in experiments performed in both wildtype mice and transgenic mice that lack eosinophils (TgPHIL mice), eosinophils can augment allergic inflammation by regulating the produc tion of T H 2type chemoattractants (including CCL17 and CCL22), which promote the recruitment of T H 2 cells, and also through their interactions with DCs 40, 41 . In addition, eosinophils release preformed cytokines (such as IL4, IL13 and IFNγ) that promote either T H 2 or T H 1 cell responses 42 . Eosinophils also promote humoral immune responses. Indeed, they are capable of priming B cells for the production of antigenspecific IgM 43 . Most recently, the production of a proliferationinducing ligand (APRIL) and IL6 by eosinophils was shown to be crucial for the support of longlived plasma cells in mouse bone marrow 44 . Interestingly, activated eosinophils from the bone marrow of adjuvantimmunized mice were found to be even more effective at supporting plasma cell survival than those from adjuvantnaive mice 45 .
Interactions with innate immune cells. Alternatively activated macrophages have a pivotal role in recruiting eosino phils to the tissues 46, 47 through the release of YM1 (also known as CHI3L3), a chitinaselike selective eosinophil chemoattractant 48, 49 . Eosinophils likewise recruit alter natively activated macrophages to, and maintain their viability in, adipose tissue 50 , promote the maturation of monocytederived DCs in vitro 51 , and are required for the accumulation of myeloid DCs and the systemic production of T H 2type cytokines in mice with allergic airway disease. The eosinophil secretory mediator EDN promotes the activation and migration of DCs 52, 53 . Eosinophils communicate extensively with tissue resident mast cells. Eosinophils and mast cells are found in close proximity to one another under homeostatic conditions in the gut, and they also colocalize in the allergic lung and in the inflamed gut in patients with Crohn's disease 54 . The bidirectional signalling that occurs between eosinophils and mast cells involves sev eral immunomodulatory mediators. These include stem cell factor (also known as KIT ligand), granule proteins, cytokines (such as granulocyte-macrophage colony stimulating factor (GMCSF), IL3, IL5 and tumour necrosis factor (TNF)), nerve growth factor and mast cell proteases. Actual physical coupling of eosinophils and mast cells has been observed both in vitro and in vivo, and this interaction prolongs eosinophil survival 54 .
Box 2 | Eosinophil development
The signals that promote the differentiation of eosinophils from bone marrow progenitors and commitment to the eosinophil lineage are not completely understood. Current models point to a unique role for interleukin-5 (IL-5) -with contributions from IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) -in promoting the expansion of the eosinophil lineage from committed progenitors in the bone marrow (reviewed in REF. 132 ).
Numerous studies have focused on transcription factor networks and the hierarchical expression of transcription factors that promote eosinophil development. Notable interactions are those that involve members of the GATA-binding protein family (including GATA1 and GATA2), as well as CCAAT/enhancer-binding proteins (such as C/EBPα and C/EBPε) and PU.1. Expression or overexpression of GATA1 or GATA2 promotes eosinophil lineage commitment and the development of myeloid progenitor cells, and deletion of a GATA-binding enhancer site in the mouse Gata1 gene results in a unique loss of the eosinophil lineage. Functional interactions between GATA1, PU.1 and C/EBPε have been reported in eosinophil promyelocyte cell lines and, more recently, researchers identified both activator and repressor isoforms of C/EBPε that modulate the differentiation of human CD34 + progenitor cells into eosinophils in vitro 133 . However, these transcription factors also have roles in supporting the development of other haematopoietic lineages. There are no known transcription factors that are uniquely dedicated to promoting eosinophil lineage commitment and differentiation.
Eosinophil lineage-committed progenitor cells have recently been identified in the bone marrow of healthy humans 134, 135 . These lineage-committed progenitors are defined as CD34 Eosinophil responses to pathogens and parasites Eosinophils and helminths: who wins? The historic view that eosinophils promote host defence against hel minths arose largely from histological images of eosino phils and parasites in tissue specimens and from in vitro studies that documented the antiparasitic activities of the eosinophil granule proteins MBP and ECP. With the development of reagents that block eosinophilia in mice (such as IL5specific antibodies) and of IL5 or eosinophildeficient mice, the picture has become more complex. For instance, the helminth Schistosoma mansoni, although not a natural mouse pathogen, can infect wildtype mice and can elicit a profound T H 2type cytokinemediated pathology and cause the accumula tion of eosinophils in tissues 55 . Although the eosino phil granule proteins ECP and MBP are toxic to both schisto somules and the larvae of S. mansoni, the manip ulation of eosinophils in mouse models had no signifi cant impact on disease development during S. mansoni infection 56, 57 . However, in Strongyloides stercoralis and
Angiostrongylus cantonensis infection models, eosino phil depletion resulted in prolonged survival of tissue based larval forms of the parasites 58, 59 . Thus, the role of eosinophils in mouse models of helminth infection remains unclear and controversial.
The interaction of eosinophils and helminths during infection in human subjects has been examined using a genomics approach 60 . The 434G>C polymorphism in the gene encoding ECP results in substitution of the cationic amino acid arginine for the neutral amino acid threonine at position 97. The genotype 434CC -which encodes the more neutral and somewhat less cytotoxic form of ECP -is found commonly among Ugandans, who live in a region endemic for S. mansoni infection. By contrast, the 434CC genotype is quite rare in Sudan, where S. mansoni is not endemic. Although this result suggests that there is no selective advantage for those individuals whose eosinophils might provide stronger antischistosomal host defence, the authors of this study determined that individuals with the 434CC genotype . Furthermore, acting together with dendritic cells (DCs), eosinophils regulate the recruitment of T helper 2 (T H 2) cells in response to allergen sensitization and challenge by producing CC-chemokine ligand 17 (CCL17) and CCL22 (REFS 40, 41) . Eosinophils also prime B cells for antigen-specific IgM production 39 and sustain long-lived plasma cells in mouse bone marrow via the production of a proliferation-inducing ligand (APRIL) and interleukin-6 (IL-6) 44, 45 . Eosinophils that are stimulated by CpG DNA induce DC maturation 51 . Indeed, the eosinophil granule protein eosinophil-derived neurotoxin (EDN) promotes the maturation and activation of DCs 52, 53 . Major basic protein (MBP) released from eosinophils activates neutrophils, causing them to release superoxide and IL-8 and increase their expression of the cell-surface integrin complement receptor 3 (CR3) 146 . Eosinophils also maintain alternatively activated macrophages in adipose tissue by producing IL-4 and IL-13 (REF. 50 ). The eosinophil granule proteins MBP, eosinophil cationic protein (ECP) and eosinophil peroxidase (EPX) activate mast cells, resulting in the release of histamine. Likewise, eosinophil-derived nerve growth factor (NGF) prolongs mast cell survival 147 .
Nurse cells
As used in this Review, this term refers to skeletal muscle cells that have been infected with the larval forms of Trichinella species parasites. A capillary network forms around the nurse cells, which provides crucial support for the parasites as they develop.
Neutrophil extracellular traps
(NETs). Fibrous networks that are released into the extracellular environment by neutrophils. They are composed mainly of DNA, but also contain proteins from neutrophil granules. NETs act as a mesh that traps microorganisms and exposes them to neutrophil-derived effector molecules.
developed substantially less liver fibrosis secondary to S. mansoni infection. As such, the selective advantage may be for those individuals whose eosinophils promote less collateral tissue damage when faced with a similar pathogen burden. Similarly, cerebral malaria, a severe outcome of infection with Plasmodium falciparum, is also associated with eosinophilia and elevated serum levels of ECP. The haplotype strongly associated with susceptibility to severe disease encodes arginine at posi tion 97 and thus the more cationic form of ECP 61 . The explanation of this finding awaits further clarification of the role of eosinophils in cerebral malaria.
The most recent developments in this field have exploited current concepts of eosinophils as immuno modulatory cells. In wildtype mice, infection with Trichinella spiralis induces eosinophil recruitment to the infected tissues and the formation of nurse cells in skeletal muscle. In eosinophildeficient ΔdblGATA and TgPHIL mice, T. spiralis larvae do not survive, largely owing to the diminished recruitment of T H 2 cells and a concomitant increase in the activity of induc ible nitric oxide synthase (iNOS) and the synthesis of nitric oxide in local macrophages 6, 7 . One interpretation of these results is that the parasites recruit eosinophils to support their own persistence and survival; another possibility is that eosinophils are recruited to main tain homeostatic balance by limiting the development of T H 1type immune responses that lead to oxidative damage and tissue destruction. How the parasite elic its this response and whether this finding is unique to Trichinella species are important subjects for future consideration. In addition, it will be interesting to address whether the mechanisms by which T. spiralis recruits eosinophils to muscle tissue, the activation state of the eosinophils at this site and the mediators released in situ are similar to those involved in eosinophilic inflammatory myopathies. Eosinophils and bacteria: pathogens, probiotics and the microbiome. Early experiments carried out in vitro docu mented the bactericidal properties of the cationic eosino phil granule proteins MBP and ECP 62, 63 . Subsequent studies exploring the mechanisms involved showed that ECP has a specific affinity for bacterial lipopolysaccharide and peptidoglycan and can agglutinate Gramnegative bacterial pathogens 64 . More recently, in vivo studies of the interaction of eosinophils with bacteria documented the catapultlike release of structures resembling neutrophil extracellular traps (NETs) from eosinophils, and this was associated with protection from the lethal sequelae of caecal ligation 65 . In contrast to NETs, which are com posed primarily of nuclear DNA and neutrophilspecific proteins, eosinophil NETlike structures are composed of mitochondrial DNA, MBP and ECP 66 . Whether eosino phils and their secretory mediators have physiological bactericidal functions in vivo requires further study. Although eosinophilenriched IL5transgenic mice were protected from the lethal sequelae of Pseudomonas aeruginosa infection 67 , recent findings suggest that IL5mediated protection during bacterial sepsis might be mediated by cells other than eosinophils 68 .
Recently, tremendous interest has developed regard ing the immunomodulatory impact of probiotic or healthpromoting bacteria. Although the mechanisms remain uncertain, oral administration of live probiotic Lactobacillus or Bifidobacterium species suppressed eosinophil recruitment in mouse models of allergic airway disease 69, 70 . However, the therapeutic impact of probiotics in human studies of allergic disease has been less impressive. Indeed, in a recent prospective study in which allergic children were provided with oral supple mentation with Lactobacillus rhamnosus GG or a pla cebo control, no significant differences were recorded in the number of asthma exacerbations per year, the number of days on medication, the peripheral blood eosinophil count or the serum ECP levels 71 . In parallel, the interactions between commensal bacteria and tissueresident eosinophils in the intes tine have been the subject of recent investigations. Mice raised under germfree conditions exhibited exaggerated eosinophilia in a model of allergic airway inflammation; this phenotype was reversed when the gastrointestinal tract was colonized with normal microflora 72 . Likewise, a large prospective study involving over 400 healthy infants 73 concluded that individuals with greater bacte rial diversity in the gastrointestinal tract had a lower risk of developing allergic sensitization later in life.
Eosinophils and viruses.
Human respiratory virusessuch as influenza virus, parainfluenza virus, respira tory syncytial virus (RSV), coronaviruses and, most prominently, rhinoviruses -are among the most com mon causes of asthma exacerbation. Although asthma typically involves dysregulated eosinophil recruitment, and eosinophils are generally perceived as promot ing disease pathology in this setting, the outcome of eosinophil-virus interactions has not been fully explored. A recent concept to emerge is that eosinophils and their secretory mediators may have a role in pro moting antiviral host defence. An initial study showed that eosinophil secretory mediators decrease the ability of RSV to infect target host epithelial cells 74 . This was followed by a later report 75 that found that eosinophils that were induced by allergen sensitization decreased viral loads during parainfluenza virus infection in a guinea pig asthma model. Accelerated clearance of RSV has been demonstrated in the lungs of eosinophil enriched Cd2IL5transgenic mice (which over express IL5 under the control of the Cd2 promoter) 76 , and activated eosinophils protect mice from the lethal sequelae of acute pneumovirus infection (C. Percopo, K.D.D., S. Ochkur, J. Lee, J. Domachowske and H.F.R., unpublished observations). Moreover, both human and mouse eosinophils release immunomodulatory mediators, notably IL6, in response to infection with respiratory virus pathogens 77, 78 . Hypereosinophilia is a frequent finding in latestage HIV infection, typically in association with allergic and/or immune dysfunction and low CD4 + T cell counts 79 . Furthermore, one study documented large numbers of CD8 + CD30
+ T cell clones expressing T H 2type cytokines (including IL5) in HIVpositive donors 80 , although another did not confirm this finding 81 . Interestingly, the granule protein EDN has been shown to have HIV inhibitory activity 82 . However, the precise mechanisms by which eosinophils and their secretory mediators interact with viral pathogens remain to be elucidated.
Eosinophils and disease
There is extensive literature on eosinophil dysregulation associated with diseases such as asthma and eosinophilic oesophagitis. Although we know a substantial amount regarding how eosinophils develop and how they are recruited into various organs and tissues, there is a lack of understanding regarding the roles of eosinophils in eosinophilassociated diseases -even the relatively common ones. Targeting eosinophils therapeutically has revealed the complex and heterogeneous nature of eosino philassociated diseases. We have selected the examples that follow to illustrate these principles; a more extensive list of diseases associated with eosinophilia is included in Supplementary information S1 (table) (see also REF. 83 ).
Eosinophils and asthma.
Asthma is a chronic inflam matory disease that is characterized by reversible airway obstruction and airway hyperreactivity in response to nonspecific spasmogenic stimuli. Eosinophils are a com mon feature of the inflammatory response that occurs in asthma, as they are recruited to the lungs and airways by cytokines that are released from activated T H 2 cells and by a range of chemokines, most notably those of the eotaxin family.
A role for eosinophils in promoting the pathogenesis of some forms of asthma is supported by a large body of literature, primarily from studies of acute and chronic allergenchallenged mouse models of allergic airway disease 84, 85 . Antigen sensitization and challenge, typi cally with ovalbumin or Aspergillus species, induces an allergic airway disease that replicates many of the hall mark features of allergic asthma, including increased numbers of cytokinesecreting T H 2 cells and eosinophils in the airways, mucus hypersecretion and airway hyper reactivity. Chronic exposure to these antigens results in features of airway remodelling, including fibrosis and thickening of the basement membrane. Collectively, these studies suggest that targeting eosinophils them selves, eosinophil migration and/or eosinophilopoiesis should provide therapeutic benefit for the treatment of asthma.
These findings ultimately led to the development of two humanized IL5specific monoclonal antibodies, mepolizumab and reslizumab, which block the bind ing of IL5 to IL5Rα. In two of the earliest studies 86, 87 , mepolizumab was administered to patients with mild atopic asthma and to healthy volunteers. In response, eosinophil numbers in the bronchial mucosa decreased by 50%, an observation that correlated with reduced levels of the prominent profibrotic eosinophil secre tory cytokine, transforming growth factorβ1 (TGFβ1), and with diminished deposition of extracellular matrix proteins. Similarly, another study showed that mepoli zumab suppressed eosinophil maturation in the bone marrow and resulted in fewer CD34 +
IL5Rα
+ eosinophil progenitors in the lungs 87 .
In initial clinical trials, small cohorts of patients with mild or moderate asthma were treated with mepolizu mab or reslizumab, respectively 88.89 . Both mono clonal antibodies were well tolerated by patients, and both reduced eosinophil numbers in the blood and airways. However, no objective measures of clinical improvement emerged
.
In part owing to the results from these clinical trials, the complex nature of the inflammatory response in asthma has been revisited 90, 91 . Four distinct phenotypes based on the inflammatory cell profile in induced sputum have been introduced (BOX 3) and, likewise, catego ries of asthma endogenous phenotypes (referred to as endotypes) based on molecular mechanisms and environmental influences have been defined. In subse quent studies, the therapeutic potential of IL5specific mono clonal antibodies was explored in a subset of asth ma tics who were steroid dependent and had persistent sputum eosinophilia [91] [92] [93] [94] [95] . In these trials, the numbers of eosinophils in sputum fell to almost zero, a finding that correlated with decreased frequencies of exacerbations, a steroidsparing effect, improved lung function and longterm improvements in asthma control.
These studies highlight the heterogeneous nature of asthma 90, 91 and, most importantly, define a clinical phenotype -known as steroidresistant eosinophilic asthma -in which eosinophils make a clear and direct contribution to current disease and its management. New approaches that target eosinophils directly, such Box 3 | Eosinophils and asthma: complexity, controversy and consensus Eosinophil accumulation in the airway wall and lumen is a prominent feature of asthma. However, the part played by eosinophils in promoting the cardinal features of this disorder has been the subject of recent controversy. Most available evidence from mouse models suggests that the activation of eosinophils contributes directly to the mucous production, bronchoconstriction and airway dysfunction and remodelling that are characteristic of allergic asthma. As such, eosinophils and molecules that regulate eosinophil development and recruitment are perceived as appropriate targets for therapeutic ablation 137, 138 . One conflicting perspective emerged from studies of allergic airway disease in the two eosinophil-deficient mouse models (see TABLE 1 ). TgPHIL mice that were sensitized and challenged with an allergen responded as anticipated, with diminished mucous production and lower levels of airway hyperreactivity compared with wild-type mice 11 . By contrast, initial results from ΔdblGATA mice suggested that eosinophils had no role in promoting acute airway responses 139 . These differences, once highly controversial, have since been attributed to variations in the mouse background strain 140 . At the same time, results from the first safety and efficacy trials of humanized monoclonal antibodies specific for interleukin-5 (IL-5) were published 87, 88 . The target populations for these trials were broadly defined, and included individuals with mild to moderate asthma. In these cohorts, the IL-5-specific antibodies were quite effective at removing eosinophils from the blood and the airways; however, no objective clinical benefits emerged. Although it was possible to conclude that eosinophils are unimportant in functional asthma pathogenesis, it was also evident that a large portion (up to 50%) of the eosinophils present in lung tissue were not removed and remained in the tissue both during and following the completion of the IL-5-specific antibody therapy.
The recognition of heterogeneity within the group of diseases currently classified as asthma has led to the introduction of the concept of disease endotypes 91 , as well as of specific inflammatory phenotypes (namely, neutrophilic asthma, eosinophilic asthma, mixed granulocytic asthma and paucigranulocytic asthma) 90 . One of the most recent findings is that patients with poorly controlled, steroid-resistant eosinophilic asthma respond to IL-5-specific monoclonal antibody therapy with eosinophil clearance and marked improvements in important objective measures of disease [92] [93] [94] [95] .
as the cytotoxic IL5Rαspecific monoclonal antibody benralizumab, or indirectly, such as the IL13specific mono clonal antibody lebrikizumab, may further enhance therapeutic outcomes 96, 97 . Eosinophilic oesophagitis. Eosinophils are normally found in the gastrointestinal tract, notably in the caecum, but not in the oesophagus. First described by Landres and colleagues in 1978, eosinophilic oesophagitis is the most common of the eosinophilassociated gastro intestinal diseases. In 2007, an international consortium -the First International Gastrointestinal Eosinophil Research Symposium (FIGERS) -published consen sus guidelines for diagnosis, which were revised in 2011. These criteria include: clinical evidence of oesophageal dysfunction (including dysphagia, abdominal pain and/or food bolus impaction); 2-4 biopsy samples from the proximal and distal oesophagus with ≥15 eosinophils per field at ×400 magnification; and no response to 6-8 weeks of highdose protonpump inhibi tor therapy, ruling out gastrooesophageal reflux disease. As we focus here on eosinophilmediated mechanisms, we refer readers to a recent review on the complete natural history of eosinophilic oesophagitis 98 .
All evidence points to dysregulated eosinophilia as being central to the pathophysiology of eosinophilic oesophagitis. The aetiology appears to be dependent on the T H 2type cytokines IL5 and IL13. Patients often report concurrent allergic responses to food and air borne allergens, along with a family history of allergy, and there is an unexplained male predominance. Although absolute eosinophil numbers in biopsy sam ples at any given time may or may not correlate directly with disease severity, evidence of eosinophil activa tion -including the presence of extracellular granules and degranulated cationic proteins (such as MBP) -is prominent in tissue biopsy samples 99 . The eosinophil chemoattractant CCL26 (also known as eotaxin 3) is a prominent biomarker of eosinophilic oesophagi tis. Indeed, CCL26 is highly upregulated in diseased tissues and also in peripheral blood cells in patients with this disorder. A singlenucleotide polymorphism (2,496T>G) in the 3ʹ untranslated region of the gene encoding CCL26 has been associated with increased susceptibility to eosinophilic oesophagitis, although the mechanisms involved are not yet known 100 . Susceptibility to eosinophilic oesophagitis has also been correlated with polymorphisms in the gene encoding TSLP 101 . There are several mouse models of eosinophilic oesophagitis. Some of these models use oral or intranasal delivery of allergens to elicit tissue pathology, and oth ers promote eosinophil recruitment to the oesophagus via the overexpression of IL5 or IL13. Among these models, one uses repeated intranasal delivery of fungal or insect aeroallergens 102, 103 , which induces the expression of T H 2type cytokines and the eotaxin family member CCL11 (mice do not express CCL26), resulting in eosino phil recruitment to the oesophagus. Another mouse model involves systemic sensitization with ovalbumin in aluminium hydroxide adjuvant followed by repeated intraoesophageal challenge 104 , which induces eosinophil recruitment associated with angiogenesis, basal zone hyperplasia and tissue fibrosis. Interestingly, although the administration of eosinophildepleting SIGLECF specific antibodies to these mice inhibits eosinophil recruitment and the associated tissue remodelling 104 , in another investigation, in which oesophageal remodelling was driven by lungspecific expression IL13, no role for eosinophils was observed 105 . Similarly, ablation of CD4 + T cells -which presumably leads to a reduction in the levels of T H 2type cytokines -has only a limited impact on the recruitment of eosinophils to the oesophagus after chronic administration of Aspergillus species antigens 102 . Among the issues to be addressed in future studies is the role of eosinophil degranulation into the oesophageal tis sue in these mouse models. Furthermore, mouse mod els that incorporate relevant clinical symptoms, such as failure to thrive, would certainly be of significant value.
Current therapies for patients with eosinophilic oesophagitis include the introduction of an elemen tal diet and treatment with steroids, which target the global inflammatory response and have an impact on eosinophilderived cytokines 106 . Therapies that specifi cally target eosinophils are also being tested. For exam ple, a randomized placebocontrolled doubleblind trial in which adults with eosinophilic oesophagitis were treated with a humanized IL5specific monoclonal antibody (mepolizumab) resulted in a reduction in oesophageal inflammation and the reversal of tissue remodelling, but only minimal relief of symptoms 107 . Similar results were obtained in a prospective study in children, with clinical improvement observed in both experimental and placebo groups 108 . Interestingly, mepoli zumab did not deplete eosinophils found in the duodenal mucosa of these patients 109 . However, the aforementioned studies suggest that this disorder may be primarily regu lated by CCL26. As with asthma, the stratification of patients into subgroups that respond to specific therapies may ultimately improve clinical outcomes.
Eosinophilic myopathies. These conditions are among the most rare and poorly characterized of the eosino philrelated disorders, and include eosinophilic fas ciitis (also known as Shulman's syndrome), toxic oil syndrome and eosinophilia-myalgia syndrome 110 (BOX 4). Although eosinophils are associated with these conditions, it is not clear how they are recruited to the affected tissue or what their contributions are to the pathology observed.
Eosinophilic myositis is a relatively rare condition in which the infiltration of muscle tissue by eosinophils is observed, sometimes in association with peripheral blood and bone marrow eosinophilia. The disease can result from helminth infection, or it can be toxin induced or idiopathic in nature. Recently, specific mutations in the gene encoding calpain 3 were identi fied in association with idiopathic eosinophilic myosi tis 111 . Calpain 3 is a musclespecific neutral cysteine protease that interacts with intracellular myofibril lar proteins and has a role in sarcomere adaptation. However, there is no direct or obvious relationship between the actions of this enzyme and eosinophils or eosinophilia. It is not clear why mutations in calpain 3 result in signals that elicit eosinophil accumulation, what these signals might be, whether eosinophils are a primary or indirect target, and whether eosinophils are promoting tissue damage or altering the local immune status. One possibility is that inflamed, damaged mus cle tissue releases endogenous alarmins (such as IL33 and/or HMGB1) that activate innate immune signal ling pathways that lead to peripheral blood and tissue eosinophilia. Of note, limbgirdle muscular dystrophy type 2A, which is a common autosomal recessive form of muscular dystrophy, has also been directly linked to mutations in the gene encoding calpain 3. Although eosinophils do not have a prominent role in this dis order, transient eosinophilia has been reported in the early stages of the disease. Similarly, no infiltra tion of eosinophils into muscle tissue was reported in calpain 3deficient mice 112 , although this observation should be reassessed in other mouse strains.
Hypereosinophilic syndromes. Hypereosinophilic syn dromes are disorders of eosinophil haematopoiesis that result in hypereosinophilia (defined as >1,500 eosino phils per mm 3 ) in peripheral blood in the absence of any known aetiology. Although these disorders were recognized early on as clinically heterogeneous, recent studies have revealed the molecular basis for a few of the distinct phenotypes. The identification of myeloprolifera tive hypereosinophilic syndrome (MHES) emerged from the dramatic therapeutic responses observed in a subset of patients with hypereosinophilic syndrome following empirical treatment with imatinib, a tyrosine kinase inhibitor first developed for the treatment of chronic myeloid leukaemia 113 . This clinical observation led to the detection of a deletion in chromosome 4 that results in the fusion of the genes encoding premRNA 3ʹend processing factor FIP1 (FIP1L1) and plateletderived growth factor receptorα (PDGFRA) 114 . This leads to the production of a FIP1L1-PDGFRA fusion protein that constitutively activates proliferation and survival path ways, resulting in the clonal proliferation of eosinophils, elevated serum levels of tryptase and vitamin B12 (also known as cobalamin), severe peripheral eosinophilia and endorgan damage, the most severe form of which is endomyocardial fibrosis. Other fusion kinases have also been identified in individuals with MHES; other individ uals display clinical symptoms consistent with MHES but without a clear molecular diagnosis. Thus far, all of the PDGFRA or PDGFRBderived mutant fusion proteins that have been identified in humans have been associated with eosinophilia, for reasons that remain obscure.
The constitutive cellular activation and prolifera tion promoted by the FIP1L1-PDGFRA fusion protein has been explored in cellculture models. For example, Ba/F3 immortalized mouse proB cells require the cytokine IL3 for survival and proliferation in culture, but stable expression of the FIP1L1-PDGFRA fusion gene activates intracellular signalling pathways and eliminates the requirement for this cytokine 113 . Likewise, imatinib inhibits the growth of the human eosinophil leukaemia EoL1 cell line, which expresses the FIP1L1-PDGFRA fusion protein 115 . Most intriguingly, the uncontrolled activity of the fusion protein lies within the PDGFRA component, as the fusion eliminates an inhibitory juxtamembrane region encoded by exon 12 of the PDGFRA gene, resulting in constitutive signalling by PDGFRA in the absence of its ligand 116 . In contrast to the myeloproliferative variants, eosino philia in lymphocyticvariant hypereosinophilic syn drome (LHES) results from aberrantly activated T cell clones that constitutively produce eosinophilopoietic cytokines, including IL5. The resulting eosinophilia is thus reactive. The aberrant T cell clones (which typi cally have a CD3 − CD4 + phenotype) are also associated with elevated serum levels of IgE and CCL17, and elicit predominantly skin manifestations, including pruritus, eczema, erythroderma, urticaria and angiooedema. Individuals with this diagnosis respond to treatment with steroids, with cytotoxic agents (such as hydroxy urea) and with mepolizumab 117 , which reduced the requirement for corticosteroids in clinical studies.
These two defined variants of hypereosinophilic syndrome currently represent a minority of cases. Indeed, a recent study showed that FIP1L1-PDGFRA fusions were associated with only 11% of cases of hyper eosinophilic syndrome, and LHES accounted for only 17% of cases 118 . The classification of hypereosinophilic syndrome is currently a work in progress, and attempts are being made to balance the clinical diagnosis with the predicted response to therapy 119 .
In an initial mouse model, bone marrow transplan tation using haematopoietic progenitors that had been retrovirally transduced with FIP1L1-PDGFRA resulted in myeloproliferative disease 120 . Another group created a model that combines features of both myeloprolifera tive and lymphocyticvariant disease 121 by transducing
Box 4 | Eosinophilia-myalgia syndrome
Eosinophilia-myalgia syndrome (EMS) is a multisystem disorder that was first formally documented in a 1989 report of three cases in which eosinophilia and myalgias were connected to the ingestion of l-tryptophan dietary supplements 141 . Symptoms included severe muscle pain accompanied by profound peripheral eosinophilia. By 1990, more than 1,000 cases had been identified. The US Centers for Disease Control and Prevention defined EMS by three criteria: peripheral eosinophilia of ≥10 9 eosinophils per litre of blood; generalized myalgias of sufficient severity to interfere with daily activities; and the absence of an infectious or neoplastic aetiology. Although a specific impurity (1,1ʹ-ethylidenebis[tryptophan]; also known as peak E) in l-tryptophan from one dietary supplement supplier was identified 142 , there has never been closure on a number of issues, including the disease-eliciting potential of this impurity (or of l-tryptophan itself) in a robust animal model of disease. Similarly, there is no definitive information on the molecular signals that promote eosinophilia and eosinophil tissue infiltration in EMS, nor is it clear whether the eosinophils were in fact causing the acute and/or chronic symptoms. Other theories have emerged, including those featuring tryptophan metabolites such as indoleamine as inhibitors of histamine degradation, leading to eosinophilia and myalgias 143 . Likewise, age (>45 years) and the HLA alleles DRB1*03, DRB1*04 and DQA1*0601 have been identified as risk factors for the development of EMS No epidemic has ensued since that time, although one recent case report has appeared 145 in which l-tryptophan was associated with eosinophilia, the recruitment and degranulation of eosinophils in muscle tissue, and muscle fibrosis, consistent with the diagnosis of EMS.
haematopoietic progenitors from Cd2IL5transgenic mice with FIP1L1-PDGFRA, which resulted in profound peripheral eosinophilia in association with tissue infil tration. Most recently, mice lacking the serine/threonine kinase NIK (also known as MAP3K14) were found to develop a CD4 + T celldependent blood and tissue eosinophilia 122 . However, future studies will be necessary to determine whether these mouse models will be use ful in identifying the disease mechanisms underlying distinct hypereosinophilic syndromes.
Eosinophils: changing perspectives
The field of eosinophil research is one of changing per spectives and emerging new directions. Eosinophils are clearly capable of more sophisticated immune functions than previously thought, as shown by their nuanced degranulation responses to distinct stimuli and their complex interactions with other leukocytes and pathogens. Both successful and unsuccessful attempts to target eosinophils have yielded remark able insights into disease pathogenesis. Asthma and hypereosinophilic syndromes are now understood to be complex heterogeneous disorders that require tailored therapeutic strategies. Assessing the role of endogenous and exogenous PRR ligands in eosino phil responses and clarifying the relationship between eosinophil degranulation and tissue remodelling will be important goals for future research. A better understanding of these and other aspects of eosinophil biology will aid the development of new therapeutic strategies for diseases characterized by eosinophil dysregulation.
